News

Through this collaboration, Incyte and Abramson have agreed to bring together the knowledge and expertise of their leading drug discovery and development scientists to conduct collaborative research aimed

The study showed that patients with well-controlled asthma have been able to change to the once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI) 100/25, an inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA)

The trial met its objectives and identified a Phase 2 dose regimen. Celiac disease is an immune-mediated gastrointestinal disease caused by dietary gluten predominantly in individuals who carry

This financing was led by Topspin Biotech Fund and a group of investors with Euclidean Capital, with participation from existing investors InterWest Partners, OrbiMed Advisors, and Osage University

The phase 3 ADAPT clinical trial, which is assessing rocapuldencel-T in combination with sunitinib/standard-of-care for the treatment of metastatic renal cell carcinoma (mRCC), has been concluded as futility

Currently, Inotuzumab ozogamicin is being assessed for treatment of adult patients with acute lymphoblastic leukemia (ALL) both in relapsed and refractory B-cell precursor forms. The drug will now

AGS-v is intended to provide broad protection against a range of mosquito-transmitted diseases, such as Zika, malaria, West Nile fever and dengue fever, and to hinder the ability

Under the agreement, Abzena will manufacture Magacizumab, an antibody created using the ‘Abzena inside’ Composite Human Antibody technology. Under earlier agreements with UCL, Abzena conducted the antibody humanization and

Alecensa, which is an oral medicine produced at Chugai Kamakura, is being developed for people with NSCLC whose tumours are identified as ALK-positive. The European Commission has granted approval